

# Sebastian Schneeweiss

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8414270/publications.pdf>

Version: 2024-02-01

339  
papers

27,394  
citations

7672

79  
h-index

8034

154  
g-index

347  
all docs

347  
docs citations

347  
times ranked

26865  
citing authors

#	ARTICLE	IF	CITATIONS
1	Variable Selection for Propensity Score Models. American Journal of Epidemiology, 2006, 163, 1149-1156.	1.6	1,618
2	A review of uses of health care utilization databases for epidemiologic research on therapeutics. Journal of Clinical Epidemiology, 2005, 58, 323-337.	2.4	1,041
3	Risk of Death in Elderly Users of Conventional vs. Atypical Antipsychotic Medications. New England Journal of Medicine, 2005, 353, 2335-2341.	13.9	871
4	High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data. Epidemiology, 2009, 20, 512-522.	1.2	870
5	A combined comorbidity score predicted mortality in elderly patients better than existing scores. Journal of Clinical Epidemiology, 2011, 64, 749-759.	2.4	728
6	Performance of Comorbidity Scores to Control for Confounding in Epidemiologic Studies using Claims Data. American Journal of Epidemiology, 2001, 154, 854-864.	1.6	646
7	Full Coverage for Preventive Medications after Myocardial Infarction. New England Journal of Medicine, 2011, 365, 2088-2097.	13.9	622
8	Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiology and Drug Safety, 2006, 15, 291-303.	0.9	585
9	Repeated hospitalizations predict mortality in the community population with heart failure. American Heart Journal, 2007, 154, 260-266.	1.2	497
10	Relationship Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older Adults. Circulation, 2004, 109, 2068-2073.	1.6	493
11	Accuracy of medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. American Heart Journal, 2004, 148, 99-104.	1.2	489
12	Use of comorbidity scores for control of confounding in studies using administrative databases. International Journal of Epidemiology, 2000, 29, 891-898.	0.9	359
13	Patterns of cardiovascular risk in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2006, 65, 1608-1612.	0.5	341
14	Association Between Disease-Modifying Antirheumatic Drugs and Diabetes Risk in Patients With Rheumatoid Arthritis and Psoriasis. JAMA - Journal of the American Medical Association, 2011, 305, 2525.	3.8	332
15	Aprotinin during Coronary-Artery Bypass Grafting and Risk of Death. New England Journal of Medicine, 2008, 358, 771-783.	13.9	331
16	Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. Cmaj, 2007, 176, 627-632.	0.9	305
17	Confounding Control in Healthcare Database Research. Medical Care, 2010, 48, S114-S120.	1.1	291
18	Instrumental variable methods in comparative safety and effectiveness research. Pharmacoepidemiology and Drug Safety, 2010, 19, 537-554.	0.9	288

#	ARTICLE	IF	CITATIONS
19	Improved Comorbidity Adjustment for Predicting Mortality in Medicare Populations. <i>Health Services Research</i> , 2003, 38, 1103-1120.	1.0	273
20	Anti-tumor necrosis factor $\hat{\pm}$ therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2007, 56, 1754-1764.	6.7	270
21	Learning from Big Health Care Data. <i>New England Journal of Medicine</i> , 2014, 370, 2161-2163.	13.9	264
22	Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor. <i>New England Journal of Medicine</i> , 2017, 376, 2300-2302.	13.9	256
23	Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-SPE Special Task Force on Real-World Evidence in Health Care Decision Making. <i>Value in Health</i> , 2017, 20, 1003-1008.	0.1	243
24	Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. <i>European Journal of Clinical Pharmacology</i> , 2002, 58, 285-291.	0.8	236
25	Tumor necrosis factor $\hat{\pm}$ antagonist use and cancer in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006, 54, 2757-2764.	6.7	228
26	Increasing Levels of Restriction in Pharmacoepidemiologic Database Studies of Elderly and Comparison With Randomized Trial Results. <i>Medical Care</i> , 2007, 45, S131-S142.	1.1	228
27	A basic study design for expedited safety signal evaluation based on electronic healthcare data. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 858-868.	0.9	223
28	Cardiovascular Outcomes and Mortality in Patients Using Clopidogrel With Proton Pump Inhibitors After Percutaneous Coronary Intervention or Acute Coronary Syndrome. <i>Circulation</i> , 2009, 120, 2322-2329.	1.6	210
29	Metrics for covariate balance in cohort studies of causal effects. <i>Statistics in Medicine</i> , 2014, 33, 1685-1699.	0.8	207
30	Effects of Adjusting for Instrumental Variables on Bias and Precision of Effect Estimates. <i>American Journal of Epidemiology</i> , 2011, 174, 1213-1222.	1.6	205
31	Anticonvulsant Medications and the Risk of Suicide, Attempted Suicide, or Violent Death. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1401.	3.8	204
32	When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials?. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 924-933.	2.3	201
33	Identification of Individuals With CKD From Medicare Claims Data: A Validation Study. <i>American Journal of Kidney Diseases</i> , 2005, 46, 225-232.	2.1	198
34	Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 253-264.	1.9	196
35	Evaluating uses of data mining techniques in propensity score estimation: a simulation study. <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 546-555.	0.9	195
36	Adjusting Effect Estimates for Unmeasured Confounding with Validation Data using Propensity Score Calibration. <i>American Journal of Epidemiology</i> , 2005, 162, 279-289.	1.6	185

#	ARTICLE	IF	CITATIONS
37	Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 2114-2117.	0.5	184
38	Anorexigens and Pulmonary Hypertension in the United States. <i>Chest</i> , 2000, 117, 870-874.	0.4	183
39	The incident user design in comparative effectiveness research. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 1-6.	0.9	181
40	Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies. <i>Circulation</i> , 2021, 143, 1002-1013.	1.6	174
41	Developments in Post-marketing Comparative Effectiveness Research. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 82, 143-156.	2.3	172
42	Outcomes of Reference Pricing for Angiotensin-Convertingâ€Enzyme Inhibitors. <i>New England Journal of Medicine</i> , 2002, 346, 822-829.	13.9	164
43	From adaptive licensing to adaptive pathways: Delivering a flexible lifeâ€span approach to bring new drugs to patients. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 234-246.	2.3	160
44	Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multiâ€Database Cohort Study. <i>Arthritis and Rheumatology</i> , 2017, 69, 1154-1164.	2.9	160
45	Assessing the Comparative Effectiveness of Newly Marketed Medications: Methodological Challenges and Implications for Drug Development. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 777-790.	2.3	157
46	Validation of claimsâ€based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commerciallyâ€insured population. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 596-603.	0.9	156
47	Analytic Strategies to Adjust Confounding using Exposure Propensity Scores and Disease Risk Scores: Nonsteroidal Antiinflammatory Drugs and Short-term Mortality in the Elderly. <i>American Journal of Epidemiology</i> , 2005, 161, 891-898.	1.6	155
48	Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes. <i>JAMA Network Open</i> , 2020, 3, e1918962.	2.8	152
49	Veteran's affairs hospital discharge databases coded serious bacterial infections accurately. <i>Journal of Clinical Epidemiology</i> , 2007, 60, 397-409.	2.4	149
50	Covariate Selection in High-Dimensional Propensity Score Analyses of Treatment Effects in Small Samples. <i>American Journal of Epidemiology</i> , 2011, 173, 1404-1413.	1.6	149
51	Relationship Between COX-2 Specific Inhibitors and Hypertension. <i>Hypertension</i> , 2004, 44, 140-145.	1.3	148
52	Instrumental variables I: instrumental variables exploit natural variation in nonexperimental data to estimate causal relationships. <i>Journal of Clinical Epidemiology</i> , 2009, 62, 1226-1232.	2.4	146
53	Statins and the Risk of Lung, Breast, and Colorectal Cancer in the Elderly. <i>Circulation</i> , 2007, 115, 27-33.	1.6	145
54	Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 456-464.	0.5	139

#	ARTICLE	IF	CITATIONS
55	Instrumental Variable Analysis for Estimation of Treatment Effects With Dichotomous Outcomes. <i>American Journal of Epidemiology</i> , 2008, 169, 273-284.	1.6	132
56	Comparative Efficacy and Safety of New Oral Anticoagulants in Patients With Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 480-486.	0.9	128
57	Measurement Error Correction for Logistic Regression Models with an "Alloyed Gold Standard". <i>American Journal of Epidemiology</i> , 1997, 145, 184-196.	1.6	127
58	Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data. <i>Cancer Causes and Control</i> , 2007, 18, 561-569.	0.8	119
59	Medicaid Prior-Authorization Programs and the Use of Cyclooxygenase-2 Inhibitors. <i>New England Journal of Medicine</i> , 2004, 351, 2187-2194.	13.9	116
60	Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. <i>Journal of Clinical Epidemiology</i> , 2006, 59, 819-828.	2.4	115
61	Measuring frailty using claims data for pharmacoepidemiologic studies of mortality in older adults: evidence and recommendations. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 891-901.	0.9	114
62	Adherence to Statin Therapy Under Drug Cost Sharing in Patients With and Without Acute Myocardial Infarction. <i>Circulation</i> , 2007, 115, 2128-2135.	1.6	112
63	Evaluating the Use of Nonrandomized Real-World Data Analyses for Regulatory Decision Making. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 867-877.	2.3	112
64	The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 551-559.	0.9	111
65	Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2015, 114, 1277-1289.	1.8	110
66	Instrumental variables II: instrumental variable application—in 25 variations, the physician prescribing preference generally was strong and reduced covariate imbalance. <i>Journal of Clinical Epidemiology</i> , 2009, 62, 1233-1241.	2.4	108
67	Risk of Venous Thromboembolism in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2013, 65, 1600-1607.	1.5	108
68	Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1360-1367.	0.5	108
69	Comparative Safety of Antidepressant Agents for Children and Adolescents Regarding Suicidal Acts. <i>Pediatrics</i> , 2010, 125, 876-888.	1.0	105
70	GRACE principles: recognizing high-quality observational studies of comparative effectiveness. <i>American Journal of Managed Care</i> , 2010, 16, 467-71.	0.8	103
71	Adjusting for Unmeasured Confounders in Pharmacoepidemiologic Claims Data Using External Information. <i>Epidemiology</i> , 2005, 16, 17-24.	1.2	101
72	Performance of Propensity Score Calibration—A Simulation Study. <i>American Journal of Epidemiology</i> , 2007, 165, 1110-1118.	1.6	101

#	ARTICLE	IF	CITATIONS
73	Comparative Mortality Risk of Anemia Management Practices in Incident Hemodialysis Patients. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 857.	3.8	99
74	Tumor necrosis factor- $\alpha$ antagonist use and heart failure in elderly patients with rheumatoid arthritis. <i>American Heart Journal</i> , 2008, 156, 336-341.	1.2	98
75	The Epidemiology of Prescriptions Abandoned at the Pharmacy. <i>Annals of Internal Medicine</i> , 2010, 153, 633.	2.0	98
76	Use of Health Care Databases to Support Supplemental Indications of Approved Medications. <i>JAMA Internal Medicine</i> , 2018, 178, 55.	2.6	95
77	Potential Causes of Higher Mortality in Elderly Users of Conventional and Atypical Antipsychotic Medications. <i>Journal of the American Geriatrics Society</i> , 2008, 56, 1644-1650.	1.3	90
78	Plasmode simulation for the evaluation of pharmacoepidemiologic methods in complex healthcare databases. <i>Computational Statistics and Data Analysis</i> , 2014, 72, 219-226.	0.7	85
79	Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: An instrumental variable analysis. <i>Arthritis and Rheumatism</i> , 2006, 54, 3390-3398.	6.7	83
80	Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1968-1975.	0.5	82
81	Comparative risk of genital infections associated with sodium-glucose cotransporter-2 inhibitors. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 434-438.	2.2	82
82	Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial: Cardiovascular Safety of Linagliptin Versus Glimepiride. <i>Diabetes Care</i> , 2019, 42, 2204-2210.	4.3	81
83	Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 993-1001.	3.1	79
84	Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important?. <i>American Journal of Medicine</i> , 2003, 115, 715-720.	0.6	78
85	Measuring prevalence and incidence of chronic conditions in claims and electronic health record databases. <i>Clinical Epidemiology</i> , 2019, Volume 11, 1-15.	1.5	78
86	Association Between SSRI Use and Hip Fractures and the Effect of Residual Confounding Bias in Claims Database Studies. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 632-638.	0.7	77
87	Sudden Uncontrollable Somnolence and Medication Use in Parkinson Disease. <i>Archives of Neurology</i> , 2005, 62, 1242.	4.9	77
88	Scalable Collaborative Infrastructure for a Learning Healthcare System (SCILHS): Architecture. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2014, 21, 615-620.	2.2	76
89	Nonrandomized Real-World Evidence to Support Regulatory Decision Making: Process for a Randomized Trial Replication Project. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 817-826.	2.3	76
90	Effects of Noncardiovascular Comorbidities on Antihypertensive Use in Elderly Hypertensives. <i>Hypertension</i> , 2005, 46, 273-279.	1.3	75

#	ARTICLE	IF	CITATIONS
91	Implications of M Bias in Epidemiologic Studies: A Simulation Study. <i>American Journal of Epidemiology</i> , 2012, 176, 938-948.	1.6	75
92	Consistency of performance ranking of comorbidity adjustment scores in canadian and U.S. utilization data. <i>Journal of General Internal Medicine</i> , 2004, 19, 444-450.	1.3	74
93	Internet Surveys by Direct Mailing. <i>Social Science Computer Review</i> , 1997, 15, 242-255.	2.6	72
94	Clozapine Use and Risk of Diabetes Mellitus. <i>Journal of Clinical Psychopharmacology</i> , 2002, 22, 236-243.	0.7	72
95	Underuse of ACE Inhibitors and Angiotensin II Receptor Blockers in Elderly Patients With Diabetes. <i>American Journal of Kidney Diseases</i> , 2005, 46, 1080-1087.	2.1	72
96	Effectiveness and Safety of Apixaban Compared With Rivaroxaban for Patients With Atrial Fibrillation in Routine Practice. <i>Annals of Internal Medicine</i> , 2020, 172, 463.	2.0	72
97	The relation between bisphosphonate use and non-union of fractures of the humerus in older adults. <i>Osteoporosis International</i> , 2009, 20, 895-901.	1.3	70
98	Comparative mortality risks of antipsychotic medications in community-dwelling older adults. <i>British Journal of Psychiatry</i> , 2014, 205, 44-51.	1.7	70
99	A Case-Control Study of the Effect of Infant Feeding on Celiac Disease. <i>Annals of Nutrition and Metabolism</i> , 2001, 45, 135-142.	1.0	69
100	Comparative Safety of Antipsychotic Medications in Nursing Home Residents. <i>Journal of the American Geriatrics Society</i> , 2012, 60, 420-429.	1.3	69
101	Adjustments for Unmeasured Confounders in Pharmacoepidemiologic Database Studies Using External Information. <i>Medical Care</i> , 2007, 45, S158-S165.	1.1	68
102	Topical Treatments with Pimecrolimus, Tacrolimus and Medium- to High-Potency Corticosteroids, and Risk of Lymphoma. <i>Dermatology</i> , 2009, 219, 7-21.	0.9	68
103	Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing—Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative. <i>Value in Health</i> , 2020, 23, 1128-1136.	0.1	68
104	Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults. <i>Diabetes Care</i> , 2021, 44, 826-835.	4.3	66
105	Comparing the performance of propensity score methods in healthcare database studies with rare outcomes. <i>Statistics in Medicine</i> , 2017, 36, 1946-1963.	0.8	66
106	Variation in the Risk of Suicide Attempts and Completed Suicides by Antidepressant Agent in Adults. <i>Archives of General Psychiatry</i> , 2010, 67, 497.	13.8	65
107	Refilling and Switching of Antiepileptic Drugs and Seizure-Related Events. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 88, 347-353.	2.3	65
108	Applying propensity scores estimated in a full cohort to adjust for confounding in subgroup analyses. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 697-709.	0.9	65

#	ARTICLE	IF	CITATIONS
109	Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013–2018. <i>Diabetes Care</i> , 2020, 43, 921-924.	4.3	65
110	Claims-based studies of oral glucose-lowering medications can achieve balance in critical clinical variables only observed in electronic health records. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 974-984.	2.2	63
111	A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. <i>Journal of Clinical Epidemiology</i> , 2005, 58, 98-102.	2.4	62
112	The Effect of Altitude on Dosing and Response to Erythropoietin in ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 1389-1395.	3.0	62
113	Availability of Comparative Efficacy Data at the Time of Drug Approval in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1786.	3.8	62
114	Identification of hospitalizations for intentional self-harm when E-codes are incompletely recorded. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 1263-1275.	0.9	61
115	Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: A population-based cohort study. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 789-796.	3.1	61
116	“Threshold-crossing”: A Useful Way to Establish the Counterfactual in Clinical Trials?. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 699-712.	2.3	61
117	Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations. <i>BMJ: British Medical Journal</i> , 2004, 328, 560.	2.4	58
118	The Impact of Reducing Cardiovascular Medication Copayments on Health Spending and Resource Utilization. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1817-1824.	1.2	58
119	Using Design Thinking to Differentiate Useful From Misleading Evidence in Observational Research. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 705.	3.8	58
120	Antipsychotic Agents and Sudden Cardiac Death – How Should We Manage the Risk?. <i>New England Journal of Medicine</i> , 2009, 360, 294-296.	13.9	57
121	Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention. <i>European Heart Journal</i> , 2010, 31, 561-572.	1.0	56
122	High-dimensional versus conventional propensity scores in a comparative effectiveness study of coxibs and reduced upper gastrointestinal complications. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 549-557.	0.8	56
123	Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges. <i>Osteoporosis International</i> , 2013, 24, 237-244.	1.3	56
124	Relative Performance of Propensity Score Matching Strategies for Subgroup Analyses. <i>American Journal of Epidemiology</i> , 2018, 187, 1799-1807.	1.6	56
125	Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 74, 388-400.	2.3	55
126	Considerations for the analysis of longitudinal electronic health records linked to claims data to study the effectiveness and safety of drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 147-159.	2.3	55

#	ARTICLE	IF	CITATIONS
127	Suboptimal Antidepressant Use in the Elderly. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 118-126.	0.7	54
128	Impact of two sequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthma. <i>Clinical Therapeutics</i> , 2006, 28, 964-978.	1.1	52
129	Automated data-adaptive analytics for electronic healthcare data to study causal treatment effects. <i>Clinical Epidemiology</i> , 2018, Volume 10, 771-788.	1.5	52
130	Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. <i>Annals of Internal Medicine</i> , 2021, 174, 1528-1541.	2.0	52
131	Regularized Regression Versus the High-Dimensional Propensity Score for Confounding Adjustment in Secondary Database Analyses. <i>American Journal of Epidemiology</i> , 2015, 182, 651-659.	1.6	50
132	Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments. <i>Endocrine Reviews</i> , 2021, 42, 658-690.	8.9	50
133	Pharmacogenetic Testing in the Clinical Management of Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 427-434.	0.7	49
134	Changes in Drug Use and Out-of-Pocket Costs Associated with Medicare Part D Implementation: A Systematic Review. <i>Journal of the American Geriatrics Society</i> , 2010, 58, 1764-1779.	1.3	48
135	Improved prediction of medical expenditures and health care utilization using an updated chronic disease score and claims data. <i>Journal of Clinical Epidemiology</i> , 2013, 66, 1118-1127.	2.4	48
136	Frailty and Clinical Outcomes of Direct Oral Anticoagulants Versus Warfarin in Older Adults With Atrial Fibrillation. <i>Annals of Internal Medicine</i> , 2021, 174, 1214-1223.	2.0	48
137	Claims Data Studies of Sedative-Hypnotics and Hip Fractures in Older People: Exploring Residual Confounding Using Survey Information. <i>Journal of the American Geriatrics Society</i> , 2005, 53, 948-954.	1.3	46
138	Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations. <i>Diabetologia</i> , 2014, 57, 2237-2250.	2.9	46
139	Net Health Plan Savings From Reference Pricing for Angiotensin-Converting Enzyme Inhibitors in Elderly British Columbia Residents. <i>Medical Care</i> , 2004, 42, 653-660.	1.1	44
140	A therapeutic substitution policy for proton pump inhibitors: Clinical and economic consequences. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 379-388.	2.3	44
141	Real World Data in Adaptive Biomedical Innovation: A Framework for Generating Evidence Fit for Decision-Making. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 633-646.	2.3	44
142	Multivariate-adjusted pharmacoepidemiologic analyses of confidential information pooled from multiple health care utilization databases. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 848-857.	0.9	43
143	Drugs that inhibit gastric acid secretion may alter the course of inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 239-247.	1.9	42
144	Rationale and design of the Post-MI FREEE trial: A randomized evaluation of first-dollar drug coverage for post-myocardial infarction secondary preventive therapies. <i>American Heart Journal</i> , 2008, 156, 31-36.	1.2	41

#	ARTICLE	IF	CITATIONS
145	Active Safety Monitoring of Newly Marketed Medications in a Distributed Data Network: Application of a Semi-Automated Monitoring System. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 80-86.	2.3	41
146	Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 350-357.	2.3	41
147	What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution?. <i>Health Policy</i> , 1998, 44, 253-260.	1.4	40
148	Ventricular Arrhythmias and Cerebrovascular Events in the Elderly Using Conventional and Atypical Antipsychotic Medications. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 707-710.	0.7	40
149	Managing Drug-Risk Information " What to Do with All Those New Numbers. <i>New England Journal of Medicine</i> , 2009, 361, 647-649.	13.9	40
150	Identifying Patients With High Data Completeness to Improve Validity of Comparative Effectiveness Research in Electronic Health Records Data. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 899-905.	2.3	40
151	The risk of infection associated with tumor necrosis factor $\hat{\pm}$ antagonists: Making sense of epidemiologic evidence. <i>Arthritis and Rheumatism</i> , 2008, 58, 919-928.	6.7	38
152	No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 399-405.	1.6	37
153	Quasi-experimental longitudinal designs to evaluate drug benefit policy changes with low policy compliance. <i>Journal of Clinical Epidemiology</i> , 2002, 55, 833-841.	2.4	36
154	Changes in Drug Utilization during a Gap in Insurance Coverage: An Examination of the Medicare Part D Coverage Gap. <i>PLoS Medicine</i> , 2011, 8, e1001075.	3.9	36
155	High-dimensional propensity score algorithm in comparative effectiveness research with time-varying interventions. <i>Statistics in Medicine</i> , 2015, 34, 753-781.	0.8	36
156	Development and Preliminary Validation of a Medicare Claims-Based Model to Predict Left Ventricular Ejection Fraction Class in Patients With Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004700.	0.9	36
157	Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. <i>Cmaj</i> , 2002, 166, 737-45.	0.9	36
158	Reference drug programs: Effectiveness and policy implications. <i>Health Policy</i> , 2007, 81, 17-28.	1.4	35
159	Quantifying the Role of Adverse Events in the Mortality Difference between First and Second-Generation Antipsychotics in Older Adults: Systematic Review and Meta-Synthesis. <i>PLoS ONE</i> , 2014, 9, e105376.	1.1	35
160	From Trial to Target Populations " Calibrating Real-World Data. <i>New England Journal of Medicine</i> , 2017, 376, 1203-1205.	13.9	35
161	Use of the case-crossover design to study prolonged drug exposures and insidious outcomes. <i>Annals of Epidemiology</i> , 2004, 14, 296-303.	0.9	34
162	Explained variation in a model of therapeutic decision making is partitioned across patient, physician, and clinic factors. <i>Journal of Clinical Epidemiology</i> , 2006, 59, 18-25.	2.4	34

#	ARTICLE	IF	CITATIONS
163	Variation in Antipsychotic Treatment Choice Across US Nursing Homes. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 11-17.	0.7	34
164	Can Improved Prescription Medication Labeling Influence Adherence to Chronic Medications? An Evaluation of the Target Pharmacy Label. <i>Journal of General Internal Medicine</i> , 2009, 24, 570-578.	1.3	33
165	Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments. <i>BMC Medical Research Methodology</i> , 2012, 12, 180.	1.4	33
166	Successful Comparison of US Food and Drug Administration Sentinel Analysis Tools to Traditional Approaches in Quantifying a Known Drug-Adverse Event Association. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 558-564.	2.3	33
167	On the evaluation of drug benefits policy changes with longitudinal claims data: the policy maker's versus the clinician's perspective. <i>Health Policy</i> , 2001, 55, 97-109.	1.4	32
168	Comparative Effectiveness of Preventative Therapy for Venous Thromboembolism After Coronary Artery Bypass Graft Surgery. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 590-596.	1.4	32
169	The Effect of Transitioning to Medicare Part D Drug Coverage in Seniors Dually Eligible for Medicare and Medicaid. <i>Journal of the American Geriatrics Society</i> , 2008, 56, 2304-2310.	1.3	31
170	Medicare Beneficiaries' Knowledge of and Choices Regarding Part D, 2005 to the Present. <i>Journal of the American Geriatrics Society</i> , 2010, 58, 950-966.	1.3	31
171	Methodological Approaches to Evaluate the Impact of FDA Drug Safety Communications. <i>Drug Safety</i> , 2015, 38, 565-575.	1.4	31
172	Privacy-Maintaining Propensity Score-Based Pooling of Multiple Databases Applied to a Study of Biologics. <i>Medical Care</i> , 2010, 48, S83-S89.	1.1	30
173	No differences in cancer screening rates in patients with rheumatoid arthritis compared to the general population. <i>Arthritis and Rheumatism</i> , 2012, 64, 3076-3082.	6.7	30
174	Using Previous Medication Adherence to Predict Future Adherence. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2018, 24, 1146-1155.	0.5	29
175	Collaborative-controlled LASSO for constructing propensity score-based estimators in high-dimensional data. <i>Statistical Methods in Medical Research</i> , 2019, 28, 1044-1063.	0.7	29
176	Choosing Among Common Data Models for Real-World Data Analyses Fit for Making Decisions About the Effectiveness of Medical Products. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 827-833.	2.3	29
177	Real-World Evidence for Assessing Pharmaceutical Treatments in the Context of COVID-19. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 816-828.	2.3	29
178	First results from an intensified monitoring system to estimate drug related hospital admissions. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 196-200.	1.1	28
179	Prescription Duration After Drug Copay Changes in Older People: Methodological Aspects. <i>Journal of the American Geriatrics Society</i> , 2002, 50, 521-525.	1.3	28
180	Underuse of Controller Medications Among Children With Persistent Asthma in the Ohio Medicaid Population: Evolving Differences With New Medications. <i>Academic Pediatrics</i> , 2005, 5, 83-89.	1.7	28

#	ARTICLE	IF	CITATIONS
181	Treatment Dynamics of Newly Marketed Drugs and Implications for Comparative Effectiveness Research. <i>Value in Health</i> , 2013, 16, 1054-1062.	0.1	28
182	Patients'™ Preferences in Anticoagulant Therapy. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 912-919.	0.9	28
183	Aprotinin and the risk of death and renal dysfunction in patients undergoing cardiac surgery: a meta-analysis of epidemiologic studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2009, 18, 259-268.	0.9	27
184	Improving therapeutic effectiveness and safety through big healthcare data. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 99, 262-265.	2.3	27
185	Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem-containing medications. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 712-721.	0.9	27
186	Hypothesis-free screening of large administrative databases for unsuspected drug-outcome associations. <i>European Journal of Epidemiology</i> , 2018, 33, 545-555.	2.5	27
187	Scalable collaborative targeted learning for high-dimensional data. <i>Statistical Methods in Medical Research</i> , 2019, 28, 532-554.	0.7	27
188	Emulation Differences vs. Biases When Calibrating Real-World Evidence Findings Against Randomized Controlled Trials. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 735-737.	2.3	27
189	Metric properties of the appropriateness evaluation protocol and predictors of inappropriate hospital use in Germany: an approach using longitudinal patient data. <i>International Journal for Quality in Health Care</i> , 2002, 14, 483-492.	0.9	26
190	Comparison of Different Approaches to Confounding Adjustment in a Study on the Association of Antipsychotic Medication With Mortality in Older Nursing Home Patients. <i>American Journal of Epidemiology</i> , 2011, 174, 1089-1099.	1.6	26
191	Real-World Evidence of Treatment Effects: The Useful and the Misleading. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 43-44.	2.3	26
192	Completeness of retail pharmacy claims data: Implications for pharmacoepidemiologic studies and pharmacy practice in elderly patients. <i>Clinical Therapeutics</i> , 2009, 31, 2048-2059.	1.1	25
193	Clinical and Health Care Use Characteristics of Patients Newly Starting Allopurinol, Febuxostat, and Colchicine for the Treatment of Gout. <i>Arthritis Care and Research</i> , 2013, 65, 2008-2014.	1.5	24
194	Addressing Limitations in Observational Studies of the Association Between Glucose-Lowering Medications and All-Cause Mortality: A Review. <i>Drug Safety</i> , 2015, 38, 295-310.	1.4	24
195	Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity. <i>Drugs</i> , 2020, 80, 1961-1972.	4.9	24
196	Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA. <i>Diabetes Care</i> , 2021, 44, 1774-1782.	4.3	24
197	Understanding secondary databases: a commentary on "Sources of bias for health state characteristics in secondary databases". <i>Journal of Clinical Epidemiology</i> , 2007, 60, 648-650.	2.4	23
198	Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the United States. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1542-1551.	2.2	23

#	ARTICLE	IF	CITATIONS
199	Adherence to beta-blocker therapy under drug cost-sharing in patients with and without acute myocardial infarction. <i>American Journal of Managed Care</i> , 2007, 13, 445-52.	0.8	23
200	What if the Federal Government Negotiated Pharmaceutical Prices for Seniors? An Estimate of National Savings. <i>Journal of General Internal Medicine</i> , 2008, 23, 1435-1440.	1.3	22
201	Assessing Residual Confounding of the Association between Antipsychotic Medications and Risk of Death using Survey Data. <i>CNS Drugs</i> , 2009, 23, 171-180.	2.7	22
202	Using Real-World Data to Extrapolate Evidence From Randomized Controlled Trials. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1156-1163.	2.3	22
203	Simultaneously assessing intended and unintended treatment effects of multiple treatment options: a pragmatic "matrix design". <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 675-683.	0.9	21
204	Risk of Ischemic Cerebrovascular and Coronary Events in Adult Users of Anticonvulsant Medications in Routine Care Settings. <i>Journal of the American Heart Association</i> , 2013, 2, e000208.	1.6	21
205	Validation of claims-based algorithms for identification of high-grade cervical dysplasia and cervical cancer. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 1239-1244.	0.9	21
206	A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 619-627.	0.9	21
207	Comparison of high-dimensional confounder summary scores in comparative studies of newly marketed medications. <i>Journal of Clinical Epidemiology</i> , 2016, 76, 200-208.	2.4	21
208	Impact of an Interaction Between Clopidogrel and Selective Serotonin Reuptake Inhibitors. <i>American Journal of Cardiology</i> , 2017, 119, 651-657.	0.7	21
209	Incidence of Venous Thromboembolism in Patients With Dermatologist-Diagnosed Chronic Inflammatory Skin Diseases. <i>JAMA Dermatology</i> , 2021, 157, 805.	2.0	21
210	Rosiglitazone and Myocardial Infarction in Patients Previously Prescribed Metformin. <i>PLoS ONE</i> , 2009, 4, e6080.	1.1	20
211	Methods for Comparative Effectiveness Research/Patient-Centered Outcomes Research: From Efficacy to Effectiveness. <i>Journal of Clinical Epidemiology</i> , 2013, 66, S1-S4.	2.4	20
212	Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score-matched cohort study. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 300-311.	0.6	20
213	Validation of obesity-related diagnosis codes in claims data. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2623-2631.	2.2	20
214	Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin. <i>Annals of Internal Medicine</i> , 2022, 175, 927-937.	2.0	20
215	The Impact of Cost Sharing on Antidepressant Use Among Older Adults in British Columbia. <i>Psychiatric Services</i> , 2008, 59, 377-383.	1.1	19
216	Ensuring Patient Privacy in Data Sharing for Postapproval Research. <i>New England Journal of Medicine</i> , 2014, 371, 1644-1649.	13.9	19

#	ARTICLE	IF	CITATIONS
217	Biologic Disease-Modifying Antirheumatic Drugs and Risk of High-Grade Cervical Dysplasia and Cervical Cancer in Rheumatoid Arthritis: A Cohort Study. <i>Arthritis and Rheumatology</i> , 2016, 68, 2106-2113.	2.9	19
218	Exposure misclassification as a result of free sample drug utilization in automated claims databases and its effect on a pharmacoepidemiology study of selective COX-2 inhibitors. <i>Pharmacoepidemiology and Drug Safety</i> , 2004, 13, 695-702.	0.9	18
219	An Evaluation of the Relationship Between the Implementation of a Newly Designed Prescription Drug Label at Target Pharmacies and Health Outcomes. <i>Medical Care</i> , 2009, 47, 1031-1035.	1.1	18
220	Beneficiaries With Cardiovascular Disease and the Part D Coverage Gap. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 387-395.	0.9	18
221	"First-Wave" Bias When Conducting Active Safety Monitoring of Newly Marketed Medications with Outcome-Indexed Self-Controlled Designs. <i>American Journal of Epidemiology</i> , 2014, 180, 636-644.	1.6	18
222	Antipsychotics and Mortality: Adjusting for Mortality Risk Scores to Address Confounding by Terminal Illness. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 516-523.	1.3	18
223	Real-World Data Analytics Fit for Regulatory Decision-Making. <i>American Journal of Law and Medicine</i> , 2018, 44, 197-217.	0.5	18
224	&lt;p&gt;External Validation of an Algorithm to Identify Patients with High Data-Completeness in Electronic Health Records for Comparative Effectiveness Research&lt;/p&gt;. <i>Clinical Epidemiology</i> , 2020, Volume 12, 133-141.	1.5	18
225	Performance of a rheumatoid arthritis records-based index of severity. <i>Journal of Rheumatology</i> , 2005, 32, 1679-87.	1.0	18
226	Therapeutic delay and reduced functional status six months after thrombolysis for acute myocardial infarction. <i>American Journal of Cardiology</i> , 2004, 94, 415-420.	0.7	17
227	The Explanatory Role of Stroke as a Mediator of the Mortality Risk Difference Between Older Adults Who Initiate First- Versus Second-Generation Antipsychotic Drugs. <i>American Journal of Epidemiology</i> , 2014, 180, 847-852.	1.6	17
228	DECISION-MAKING ALIGNED WITH RAPID-CYCLE EVALUATION IN HEALTH CARE. <i>International Journal of Technology Assessment in Health Care</i> , 2015, 31, 214-222.	0.2	17
229	A Case-Crossover-Based Screening Approach to Identifying Clinically Relevant Drug-Drug Interactions in Electronic Healthcare Data. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 238-244.	2.3	17
230	A Unified Framework for Classification of Methods for Benefit-Risk Assessment. <i>Value in Health</i> , 2015, 18, 250-259.	0.1	16
231	Assessing the relative efficacy of new drugs: an emerging opportunity. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 443-444.	21.5	16
232	Clinical Outcomes of Concomitant Use of Warfarin and Selective Serotonin Reuptake Inhibitors. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 200-209.	0.7	16
233	Desmopressin and the risk of hyponatremia: A population-based cohort study. <i>PLoS Medicine</i> , 2019, 16, e1002930.	3.9	16
234	Risk of Inflammatory Arthritis After a New Diagnosis of Hidradenitis Suppurativa. <i>JAMA Dermatology</i> , 2020, 156, 342.	2.0	16

#	ARTICLE	IF	CITATIONS
235	Near-Real-Time Monitoring of New Drugs: An Application Comparing Prasugrel Versus Clopidogrel. <i>Drug Safety</i> , 2014, 37, 151-161.	1.4	15
236	Short-term risk of liver and renal injury in hospitalized patients using micafungin: a multicentre cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2938-2944.	1.3	15
237	Propensity Score Weighting Compared to Matching in a Study of Dabigatran and Warfarin. <i>Drug Safety</i> , 2017, 40, 169-181.	1.4	15
238	A review of the performance of different methods for propensity score matched subgroup analyses and a summary of their application in peer-reviewed research studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1507-1512.	0.9	15
239	Association of Medicare's Bundled Payment Reform With Changes in Use of Vitamin D Among Patients Receiving Maintenance Hemodialysis: An Interrupted Time-Series Analysis. <i>American Journal of Kidney Diseases</i> , 2018, 72, 178-187.	2.1	15
240	Discussion of Schuemie et al: "A plea to stop using the case-control design in retrospective database studies". <i>Statistics in Medicine</i> , 2019, 38, 4209-4212.	0.8	15
241	&lt;p&gt;Risk Factors for Heart Failure with Preserved or Reduced Ejection Fraction Among Medicare Beneficiaries: Application of Competing Risks Analysis and Gradient Boosted Model&lt;/p&gt;. <i>Clinical Epidemiology</i> , 2020, Volume 12, 607-616.	1.5	15
242	Sturmer et al. Respond to "Propensity Score Methods in Epidemiology". <i>American Journal of Epidemiology</i> , 2007, 165, 1122-1123.	1.6	14
243	Virtual non-enhanced dual-energy CT reconstruction may replace true non-enhanced CT scans in the setting of suspected active hemorrhage. <i>European Journal of Radiology</i> , 2018, 109, 218-222.	1.2	14
244	Assessing Health State Utilities in Elderly Patients at Cardiovascular Risk. <i>Medical Decision Making</i> , 2006, 26, 247-254.	1.2	13
245	The Effect of Altitude Change on Anemia Treatment Response in Hemodialysis Patients. <i>American Journal of Epidemiology</i> , 2011, 173, 768-777.	1.6	13
246	Adjuvant vancomycin for antibiotic prophylaxis and risk of Clostridium difficile infection after coronary artery bypass graft surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2013, 146, 472-478.	0.4	13
247	Multimodal Analysis of FDA Drug Safety Communications: Lessons from Zolpidem. <i>Drug Safety</i> , 2019, 42, 1287-1295.	1.4	13
248	Initiation of Acetylcholinesterase Inhibitors and Complications of Chronic Airways Disorders in Elderly Patients. <i>Drug Safety</i> , 2006, 29, 1077-1085.	1.4	12
249	Psychotropic medication use for behavioral symptoms of dementia. <i>Current Neurology and Neuroscience Reports</i> , 2006, 6, 490-495.	2.0	12
250	Effects of Prescription Coinsurance and Income-Based Deductibles on Net Health Plan Spending for Older Users of Inhaled Medications. <i>Medical Care</i> , 2009, 47, 508-516.	1.1	12
251	Early Steps in the Development of a Claims-Based Targeted Healthcare Safety Monitoring System and Application to Three Empirical Examples. <i>Drug Safety</i> , 2012, 35, 407-416.	1.4	12
252	Actionable Real-World Evidence to Improve Health Outcomes and Reduce Medical Spending Among Risk-Stratified Patients with Diabetes. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2019, 25, 1442-1452.	0.5	12

#	ARTICLE	IF	CITATIONS
253	Safety and Effectiveness of Dabigatran and Other Direct Oral Anticoagulants Compared With Warfarin in Patients With Atrial Fibrillation. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1405-1419.	2.3	12
254	Clinical outcomes and healthcare utilization in patients with sickle cell disease: a nationwide cohort study of Medicaid beneficiaries. <i>Annals of Hematology</i> , 2020, 99, 2497-2505.	0.8	12
255	Real-world evidence of bariatric surgery and cardiovascular benefits using electronic health records data: A lesson in bias. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1453-1462.	2.2	12
256	Comparative effectiveness and safety of sodium-glucose cotransporter-2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2320-2328.	2.2	12
257	Newly marketed medications present unique challenges for nonrandomized comparative effectiveness analyses. <i>Journal of Comparative Effectiveness Research</i> , 2012, 1, 109-111.	0.6	11
258	Updating the Evidence of the Interaction Between Clopidogrel and CYP2C19-Inhibiting Selective Serotonin Reuptake Inhibitors: A Cohort Study and Meta-Analysis. <i>Drug Safety</i> , 2017, 40, 923-932.	1.4	11
259	Reuse of data sources to evaluate drug safety signals: When is it appropriate?. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 567-569.	0.9	11
260	Claims Data Studies of Direct Oral Anticoagulants Can Achieve Balance in Important Clinical Parameters Only Observable in Electronic Health Records. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 979-993.	2.3	11
261	An Event-Based Approach for Comparing the Performance of Methods for Prospective Medical Product Monitoring. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 631-639.	0.9	10
262	Selective Serotonin Reuptake Inhibitor Use and Perioperative Bleeding and Mortality in Patients Undergoing Coronary Artery Bypass Grafting: A Cohort Study. <i>Drug Safety</i> , 2015, 38, 1075-1082.	1.4	10
263	Evaluation of Socioeconomic Status Indicators for Confounding Adjustment in Observational Studies of Medication Use. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1513-1521.	2.3	10
264	Angiotensin inhibition after myocardial infarction: Does drug class matter?. <i>Journal of General Internal Medicine</i> , 2006, 21, 1242-1247.	1.3	9
265	Comparative effectiveness and safety of antiplatelet drugs in patients with diabetes mellitus and acute coronary syndrome. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 1361-1370.	0.9	9
266	Serious infection risk in children with psoriasis on systemic treatment: A propensity score-matched population-based study. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1337-1345.	0.6	9
267	Identifying Risk Factors for Diabetic Ketoacidosis Associated with SGLT2 Inhibitors: a Nationwide Cohort Study in the USA. <i>Journal of General Internal Medicine</i> , 2021, 36, 2601-2607.	1.3	9
268	Greedy caliper propensity score matching can yield variable estimates of the treatment-outcome association: A simulation study. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 934-951.	0.9	9
269	Measuring the cost-effectiveness of lipid-lowering drugs in the elderly. <i>Contemporary Clinical Trials</i> , 2002, 23, 757-773.	2.0	8
270	Physician gender and changes in drug prescribing after the implementation of reference pricing in British Columbia. <i>Clinical Therapeutics</i> , 2003, 25, 273-284.	1.1	8

#	ARTICLE	IF	CITATIONS
271	Impact analysis of the discontinuation of reimbursement: the case of oral contraceptives. <i>Contraception</i> , 2008, 78, 399-404.	0.8	8
272	NSAID switching and short-term gastrointestinal outcome rates after the withdrawal of rofecoxib. <i>Pharmacoepidemiology and Drug Safety</i> , 2009, 18, 1134-1142.	0.9	8
273	Accuracy of identifying neutropenia diagnoses in outpatient claims data. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 709-713.	0.9	8
274	Sequential Monitoring of the Comparative Effectiveness and Safety of Dabigatran in Routine Care. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005173.	0.9	8
275	SENSITIVITY ANALYSIS OF THE DIAGNOSTIC VALUE OF ENDOSCOPIES IN CROSS-SECTIONAL STUDIES IN THE ABSENCE OF A GOLD STANDARD. <i>International Journal of Technology Assessment in Health Care</i> , 2000, 16, 834-841.	0.2	7
276	Rationale and design of the Study Assessing the Effect of Cardiovascular Medications Provided as Low-cost, Evidence-based Generic Samples (SAMPLES) trial. <i>American Heart Journal</i> , 2009, 157, 613-619.	1.2	7
277	Variation in initiating secondary prevention after myocardial infarction by hospitals and physicians, 1997 through 2004. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 1088-1097.	0.9	7
278	Instrumental variable applications using nursing home prescribing preferences in comparative effectiveness research. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 830-838.	0.9	7
279	Synergies From Integrating Randomized Controlled Trials and Real-World Data Analyses. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 914-916.	2.3	7
280	Improved CT-detection of acute bowel ischemia using frequency selective non-linear image blending. <i>Acta Radiologica Open</i> , 2017, 6, 205846011771822.	0.3	7
281	Sequential surveillance for drug safety in a regulatory environment. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 707-712.	0.9	7
282	When Randomized Clinical Trials and Real-World Evidence Say the Same: Tocilizumab and Its Cardiovascular Safety. <i>Arthritis and Rheumatology</i> , 2020, 72, 4-6.	2.9	7
283	Impact of drug cost sharing on service use and adverse clinical outcomes in elderly receiving antidepressants. <i>Journal of Mental Health Policy and Economics</i> , 2010, 13, 37-44.	0.6	7
284	Transparency of high-dimensional propensity score analyses: Guidance for diagnostics and reporting. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 411-423.	0.9	7
285	Medicare Part D's Impact on Antipsychotic Drug Use and Costs Among Elderly Patients Without Prior Drug Insurance. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 3-10.	0.7	6
286	Association Between the Part D Coverage Gap and Adverse Health Outcomes. <i>Journal of the American Geriatrics Society</i> , 2012, 60, 1408-1417.	1.3	6
287	Assessment of Confounders in Comparative Effectiveness Studies From Secondary Databases. <i>American Journal of Epidemiology</i> , 2017, 185, 474-478.	1.6	6
288	Real-world effects of medications for chronic obstructive pulmonary disease: protocol for a UK population-based non-interventional cohort study with validation against randomised trial results. <i>BMJ Open</i> , 2018, 8, e019475.	0.8	6

#	ARTICLE	IF	CITATIONS
289	Defining Exposure in Observational Studies Comparing Outcomes of Treatment Discontinuation. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004684.	0.9	6
290	Long-term risk of hepatocellular carcinoma mortality in 23220 hospitalized patients treated with micafungin or other parenteral antifungals. Journal of Antimicrobial Chemotherapy, 2020, 75, 221-228.	1.3	6
291	A novel data mining application to detect safety signals for newly approved medications in routine care of patients with diabetes. Endocrinology, Diabetes and Metabolism, 2021, 4, e00237.	1.0	6
292	Single-arm oncology trials and the nature of external controls arms. Journal of Comparative Effectiveness Research, 2021, 10, 1053-1066.	0.6	6
293	Incorporating Linked Healthcare Claims to Improve Confounding Control in a Study of In-Hospital Medication Use. Drug Safety, 2015, 38, 589-600.	1.4	5
294	Risk of connective tissue disease, morphea and systemic vasculitis in patients with hidradenitis suppurativa. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 195-202.	1.3	5
295	Clinical outcomes following bone marrow transplantation in patients with sickle cell disease: A cohort study of US Medicaid enrollees. European Journal of Haematology, 2021, 106, 273-280.	1.1	5
296	Emulation of a randomized controlled trial in ulcerative colitis with <sc>US</sc> and French claims data: Infliximab with thiopurines compared to infliximab monotherapy. Pharmacoepidemiology and Drug Safety, 2022, 31, 167-175.	0.9	5
297	Pharmaceutical cost containment with reference-based pricing: time for refinements. Cmaj, 2002, 167, 1250-1.	0.9	5
298	A Framework for Visualizing Study Designs and Data Observability in Electronic Health Record Data. Clinical Epidemiology, 2022, Volume 14, 601-608.	1.5	5
299	Sequential Value-of-Information Assessment for Prospective Drug Safety Monitoring Using Claims Databases. Medical Decision Making, 2013, 33, 949-960.	1.2	4
300	Characteristics of study design and elements that may contribute to the success of electronic safety monitoring systems. Pharmacoepidemiology and Drug Safety, 2014, 23, 1223-1225.	0.9	4
301	Initiation patterns of statin therapy among adult patients undergoing intermediate to high-risk non-cardiac surgery. Pharmacoepidemiology and Drug Safety, 2016, 25, 64-72.	0.9	4
302	Impact of drug reimbursement policies on prescribing: A case study of a newly marketed long-acting injectable antipsychotic among relapsed schizophrenia patients. Pharmacoepidemiology and Drug Safety, 2018, 27, 95-104.	0.9	4
303	Using nationally representative survey data for external adjustment of unmeasured confounders: An example using the NHANES data. Pharmacoepidemiology and Drug Safety, 2020, 29, 1151-1158.	0.9	4
304	Application of a Graphical Depiction of Longitudinal Study Designs to Managed Care Pharmacy Research. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 268-274.	0.5	4
305	Methods in pharmacoepidemiology: time-varying drug effects revisited. Pharmacoepidemiology and Drug Safety, 2006, 15, 93-94.	0.9	3
306	Time Series Evaluation of an Intervention to Increase Statin Tablet Splitting by General Practitioners. Clinical Therapeutics, 2011, 33, 235-243.	1.1	3

#	ARTICLE	IF	CITATIONS
307	Comment on "Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership". <i>Statistics in Medicine</i> , 2013, 32, 1073-1074.	0.8	3
308	Prospective Benefit-Risk Monitoring of New Drugs for Rapid Assessment of Net Favorability in Electronic Health Care Data. <i>Value in Health</i> , 2015, 18, 1063-1069.	0.1	3
309	Comparison of Benefit-Risk Assessment Methods for Prospective Monitoring of Newly Marketed Drugs: A Simulation Study. <i>Value in Health</i> , 2015, 18, 1057-1062.	0.1	3
310	Stakeholder assessment of comparative effectiveness research needs for Medicaid populations. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 465-471.	0.6	3
311	Conducting Privacy-Preserving Multivariable Propensity Score Analysis When Patient Covariate Information Is Stored in Separate Locations. <i>American Journal of Epidemiology</i> , 2017, 185, 501-510.	1.6	3
312	Simulation for Predicting Effectiveness and Safety of New Cardiovascular Drugs in Routine Care Populations. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 1008-1015.	2.3	3
313	Theory meets practice: a commentary on VanderWeele's "principles of confounder selection". <i>European Journal of Epidemiology</i> , 2019, 34, 221-222.	2.5	3
314	Response by Franklin and Schneeweiss to Letters Regarding Article, "Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative". <i>Circulation</i> , 2021, 144, e162-e163.	1.6	3
315	On the Evaluation of Drug Benefits Policy Changes with Longitudinal Claims Data. <i>Disease Management and Health Outcomes</i> , 2002, 10, 763-769.	0.3	2
316	Costs of Measuring Outcomes of Acute Hospital Care in a Longitudinal Outcomes Measurement System. <i>American Journal of Medical Quality</i> , 2003, 18, 3-9.	0.2	2
317	Methods in pharmacoepidemiology: an invited series. <i>Pharmacoepidemiology and Drug Safety</i> , 2005, 14, 453-454.	0.9	2
318	Variation in adherence to medications across the healthcare system in two comparative effectiveness research cohorts. <i>Journal of Comparative Effectiveness Research</i> , 2017, 6, 613-625.	0.6	2
319	Generalized boosted modeling to identify subgroups where effect of dabigatran versus warfarin may differ: An observational cohort study of patients with atrial fibrillation. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 383-390.	0.9	2
320	Study protocol for the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 57-66.	0.6	2
321	Using Healthcare Databases to Replicate Trial Findings for Supplemental Indications: Adalimumab in Patients with Ulcerative Colitis. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 874-884.	2.3	2
322	Evolving channeling in prescribing SGLT2 inhibitors as first-line treatment for type 2 diabetes. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 566-576.	0.9	2
323	Comment: Generic Substitution of Antiepileptic Drugs: A Systematic Review of Prospective and Retrospective Studies. <i>Annals of Pharmacotherapy</i> , 2012, 46, 303-304.	0.9	1
324	Bias in Comparative Effectiveness Studies Due to Regional Variation in Medical Practice Intensity. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, e61-4.	0.9	1

#	ARTICLE	IF	CITATIONS
325	Removal of ineligible outcome cases reduces confounding. <i>Clinical Epidemiology</i> , 2018, Volume 10, 575-579.	1.5	1
326	Non-Vitamin K Antagonist Oral Anticoagulants and Angioedema: A Cohort and Case-Crossover Study. <i>Drug Safety</i> , 2019, 42, 1355-1363.	1.4	1
327	Improving measurement of binary covariates in claims data: A simulation study. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1093-1100.	0.9	1
328	Health Advisories and Patterns of Patient Monitoring Among New Users of Antidepressant Medications. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 590-594.	0.7	0
329	Outcomes in the Era of Bare-Metal Stents vs the Era of Drug-Eluting Stents. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 33.	3.8	0
330	Response to commentary by Marcus and Gibbons. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 713-713.	0.9	0
331	Response Letter to Eltonsy and Colleagues. <i>Journal of the American Geriatrics Society</i> , 2013, 61, 848-849.	1.3	0
332	Developing alerting thresholds for prospective drug safety monitoring. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 755-762.	0.9	0
333	Posing Causal Questions When Analyzing Observational Data—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 201.	3.8	0
334	Kim et al. Respond to “Estimation With Claims-Based Frailty Indexes”. <i>American Journal of Epidemiology</i> , 2020, 189, 373-374.	1.6	0
335	Reply to the Letter by Arterburn D. et al. ("Bias in EHR-based studies: Seeing the Forest for the Trees"). <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1694-1695.	2.2	0
336	The modifying effects of adiposity on the cardiovascular safety of sulphonylureas. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2502-2512.	2.2	0
337	Medications for chronic obstructive pulmonary disease: a historical non-interventional cohort study with validation against RCT results. <i>Health Technology Assessment</i> , 2021, 25, 1-70.	1.3	0
338	Clinical Outcomes Following Bone Marrow Transplant in Patients with Sickle Cell Disease: A Cohort Study of US Medicaid Enrollees. <i>Blood</i> , 2019, 134, 2166-2166.	0.6	0
339	Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. <i>Annals of Internal Medicine</i> , 2022, 175, W4-W5.	2.0	0